Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance

Yamamoto, Sena; Kondoh, Chiharu; Nakagoshi, Hideko; Kakumen, Mayuko; Yasuhara, Kana; Nakai, Mayumi; Kodani, Naoko; Sunda, Kazumi; Higashide, Chizuru; Katayama, Megumi; Arao, Harue

doi:https://doi.org/10.1007/s10147-024-02479-2

Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance

Yamamoto, Sena; Kondoh, Chiharu; Nakagoshi, Hideko et al.

International Journal of Clinical Oncology, 2024, 6, 166

Number of Access:614（2025-08-30 00:39 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/94699

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
IntJClinOncol_6_166	pdf	None	728 KB	252	2024.03.18

Creative Commons : Attribution

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance
Creator	NRID 1000060796522 1000060796522 researchmap permalink 60796522 60796522 Scopus Author ID 57188590410 57188590410 CreatorName Yamamoto, Sena
	CreatorName Kondoh, Chiharu
	CreatorName Nakagoshi, Hideko
	CreatorName Kakumen, Mayuko
	CreatorName Yasuhara, Kana
	CreatorName Nakai, Mayumi
	CreatorName Kodani, Naoko
	CreatorName Sunda, Kazumi
	CreatorName Higashide, Chizuru
	CreatorName Katayama, Megumi
	NRID 1000050326302 1000050326302 researchmap permalink read0201 read0201 Scopus Author ID 16311856300 16311856300 CreatorName Arao, Harue
Subject	Cancer
	Financial toxicity
	Molecular targeted therapy
	Immunotherapy
Description	The version of record of this article, first published in International Journal of Clinical Oncology, is available online at Publisher’s website: https://doi.org/10.1007/s10147-024-02479-2.
Abstract	Background: Financial burden of cancer treatment can negatively affect patients and their families. This study aimed to evaluate the financial toxicity of patients treated with molecular-targeted and immune therapies and explore the relationship between financial toxicity and patient experiences associated with the financial burden of cancer treatment. Methods: This anonymous, self-administered questionnaire survey conducted across nine hospitals in Japan included patients aged 20–60 years who were receiving molecular-targeted agents or immune checkpoint inhibitors for any type of cancer for ≥ 2 months. Financial toxicity was evaluated using the COmprehensive Score for Financial Toxicity (COST). Patient experience was examined using 11 items based on previous studies. Independent factors related to financial toxicity were explored using multiple regression analyses. Results: The mean COST score was 17.0 ± 8.4, and 68 (49.3%) participants reported COST scores at or below the cutoff point. The factors contributing to financial toxicity were “hesitation regarding continuing treatment based on finances” (sβ = − 0.410, p < 0.001), “cutting through my deposits and savings” (sβ = − 0.253, p = 0.003), and “reducing spending on basics like food or clothing” (sβ = − 0.205, p = 0.046) along with comorbidities (sβ = − 0.156, p = 0.032). Conclusion: Patients receiving molecular-targeted and immune therapies are at risk of experiencing profound financial toxic- ity and a reduced quality of life. The independently related factors that we identified have the potential to serve as indicators of profound financial toxicity and the need for specialized intervention.
Publisher	Springer Science and Business Media LLC
Source Title	International Journal of Clinical Oncology
Volume (Issue)	6
Page	166
Date of Issued	2024-02-24
Language	English
Handle URL	https://hdl.handle.net/11094/94699
PISSN	13419625
eISSN	14377772
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1007/s10147-024-02479-2
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution 4.0 International License.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	International Journal of Clinical Oncology. 2024, 6, p. 166
DC.title	Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance
DC.creator	Yamamoto, Sena
	Kondoh, Chiharu
	Nakagoshi, Hideko
	Kakumen, Mayuko
	Yasuhara, Kana
	Nakai, Mayumi
	Kodani, Naoko
	Sunda, Kazumi
	Higashide, Chizuru
	Katayama, Megumi
	Arao, Harue
DC.publisher	Springer Science and Business Media LLC
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2024-02-24
DC.identifier	https://doi.org/10.1007/s10147-024-02479-2
DC.subject	Cancer
	Financial toxicity
	Molecular targeted therapy
	Immunotherapy
DC.description	The version of record of this article, first published in International Journal of Clinical Oncology, is available online at Publisher’s website: https://doi.org/10.1007/s10147-024-02479-2.
DCTERMS.abstract	Background: Financial burden of cancer treatment can negatively affect patients and their families. This study aimed to evaluate the financial toxicity of patients treated with molecular-targeted and immune therapies and explore the relationship between financial toxicity and patient experiences associated with the financial burden of cancer treatment. Methods: This anonymous, self-administered questionnaire survey conducted across nine hospitals in Japan included patients aged 20–60 years who were receiving molecular-targeted agents or immune checkpoint inhibitors for any type of cancer for ≥ 2 months. Financial toxicity was evaluated using the COmprehensive Score for Financial Toxicity (COST). Patient experience was examined using 11 items based on previous studies. Independent factors related to financial toxicity were explored using multiple regression analyses. Results: The mean COST score was 17.0 ± 8.4, and 68 (49.3%) participants reported COST scores at or below the cutoff point. The factors contributing to financial toxicity were “hesitation regarding continuing treatment based on finances” (sβ = − 0.410, p < 0.001), “cutting through my deposits and savings” (sβ = − 0.253, p = 0.003), and “reducing spending on basics like food or clothing” (sβ = − 0.205, p = 0.046) along with comorbidities (sβ = − 0.156, p = 0.032). Conclusion: Patients receiving molecular-targeted and immune therapies are at risk of experiencing profound financial toxic- ity and a reduced quality of life. The independently related factors that we identified have the potential to serve as indicators of profound financial toxicity and the need for specialized intervention.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	94699
citation_title	Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance
citation_author	Yamamoto, Sena
	Kondoh, Chiharu
	Nakagoshi, Hideko
	Kakumen, Mayuko
	Yasuhara, Kana
	Nakai, Mayumi
	Kodani, Naoko
	Sunda, Kazumi
	Higashide, Chizuru
	Katayama, Megumi
	Arao, Harue
citation_publisher	Springer Science and Business Media LLC
citation_language	English
citation_date	2024-02-24
citation_journal_title	International Journal of Clinical Oncology
citation_volume	6
citation_firstpage	166
citation_doi	https://doi.org/10.1007/s10147-024-02479-2
citation_public_url	https://hdl.handle.net/11094/94699

Financial toxicity and patient experience associated with financial burden of molecular-targeted and immune therapies for cancer: an observational study under public health insurance

Link to primary information

Item Information

Show details